Sepsis is a life-threatening condition caused by a dysregulated host response to infection, leading to organ dysfunction. This review evaluates emerging biomarkers for early diagnosis and prognosis in sepsis management, which are crucial for improving patient outcomes. Traditional biomarkers like CRP and PCT have limitations, while novel biomarkers such as circular RNAs, HOXA distal transcript antisense RNA, microRNA-486-5p, protein C, triiodothyronine, and prokineticin 2 show increased sensitivity and specificity. These biomarkers play a key role in diagnosis, guiding antibiotic therapy, and assessing treatment effectiveness. Point-of-care testing has enabled rapid biomarker application. Despite advancements, challenges remain, including biomarker variability and lack of standardized thresholds. The review highlights the importance of multi-biomarker strategies and personalized medicine in sepsis management. Large-scale validation and integration into clinical practice are advocated to maximize biomarker efficacy in future sepsis treatment. Key biomarkers include CRP, PCT, IL-6, HMGB1, PSP, presepsin, CD64, and sTREM-1, each with varying diagnostic and prognostic values. Novel biomarkers like circRNAs, HOTTIP, and miR-486-5p show promise for sepsis diagnosis and prognosis. Prognostic biomarkers such as PTX-3, ADM, and ESM-1 are also discussed, with their potential in predicting outcomes and guiding treatment. The review emphasizes the need for further research to validate these biomarkers and integrate them into clinical practice for improved sepsis management.Sepsis is a life-threatening condition caused by a dysregulated host response to infection, leading to organ dysfunction. This review evaluates emerging biomarkers for early diagnosis and prognosis in sepsis management, which are crucial for improving patient outcomes. Traditional biomarkers like CRP and PCT have limitations, while novel biomarkers such as circular RNAs, HOXA distal transcript antisense RNA, microRNA-486-5p, protein C, triiodothyronine, and prokineticin 2 show increased sensitivity and specificity. These biomarkers play a key role in diagnosis, guiding antibiotic therapy, and assessing treatment effectiveness. Point-of-care testing has enabled rapid biomarker application. Despite advancements, challenges remain, including biomarker variability and lack of standardized thresholds. The review highlights the importance of multi-biomarker strategies and personalized medicine in sepsis management. Large-scale validation and integration into clinical practice are advocated to maximize biomarker efficacy in future sepsis treatment. Key biomarkers include CRP, PCT, IL-6, HMGB1, PSP, presepsin, CD64, and sTREM-1, each with varying diagnostic and prognostic values. Novel biomarkers like circRNAs, HOTTIP, and miR-486-5p show promise for sepsis diagnosis and prognosis. Prognostic biomarkers such as PTX-3, ADM, and ESM-1 are also discussed, with their potential in predicting outcomes and guiding treatment. The review emphasizes the need for further research to validate these biomarkers and integrate them into clinical practice for improved sepsis management.